The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis

Marc G. Bingaman, Gargi D. Basu, Tiana C. Golding, Samuel K. Chong, Andrew J. Lassen, Thomas J. Kindt, Christopher A. Lipinski

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite widespread use of anti-CD20 antibodies as therapeutic agents for oncologic and autoimmune indications, precise descriptions of killing mechanisms remain incomplete. Complement-dependent cytolysis and antibody-dependent cell-mediated cytotoxicity are indicated as modes of target cell depletion; however, the importance of apoptosis induction is controversial. Studies showing that the therapeutic anti-CD20 antibody rituximab (Rituxan) mediates apoptosis of tumor cell targets in vitro after cross-linking by anti-Fc reagents suggest that enhancement strategies applied to Fc-independent activities for anti-CD20 antibodies could improve therapeutic efficacy. An anti-CD20 antibody designated DXL625, with autophilic properties such as increased binding avidity, is shown here to independently induce caspase-mediated apoptosis of an established B-cell lymphoma line in vitro. Depletion of membrane cholesterol or chelation of extracellular calcium abrogated the pro-apoptotic activity of DXL625, indicating that intact lipid rafts and calcium are required for this activity. The Fc-mediated complement-dependent and antibody-dependent cellular killing mechanisms are maintained by DXL625 despite conjugation of the parental Rituxan antibody to the autophilic DXL peptide sequence. This study shows a strategy for improving anti-CD20 immunotherapy by endowing therapeutic antibodies with self-interacting properties.

Original languageEnglish (US)
Pages (from-to)532-542
Number of pages11
JournalAnti-Cancer Drugs
Volume21
Issue number5
DOIs
StatePublished - Jun 2010

Fingerprint

Anti-Idiotypic Antibodies
Apoptosis
Lipids
Antibodies
Calcium
Antibody-Dependent Cell Cytotoxicity
B-Cell Lymphoma
Therapeutics
Caspases
Immunotherapy
Cholesterol
Cell Line
Peptides
Membranes
Rituximab
Neoplasms
In Vitro Techniques

Keywords

  • Apoptosis
  • CD20 receptor
  • DXL625
  • Rituxan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Bingaman, M. G., Basu, G. D., Golding, T. C., Chong, S. K., Lassen, A. J., Kindt, T. J., & Lipinski, C. A. (2010). The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. Anti-Cancer Drugs, 21(5), 532-542. https://doi.org/10.1097/CAD.0b013e328337d485

The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. / Bingaman, Marc G.; Basu, Gargi D.; Golding, Tiana C.; Chong, Samuel K.; Lassen, Andrew J.; Kindt, Thomas J.; Lipinski, Christopher A.

In: Anti-Cancer Drugs, Vol. 21, No. 5, 06.2010, p. 532-542.

Research output: Contribution to journalArticle

Bingaman, MG, Basu, GD, Golding, TC, Chong, SK, Lassen, AJ, Kindt, TJ & Lipinski, CA 2010, 'The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis', Anti-Cancer Drugs, vol. 21, no. 5, pp. 532-542. https://doi.org/10.1097/CAD.0b013e328337d485
Bingaman, Marc G. ; Basu, Gargi D. ; Golding, Tiana C. ; Chong, Samuel K. ; Lassen, Andrew J. ; Kindt, Thomas J. ; Lipinski, Christopher A. / The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. In: Anti-Cancer Drugs. 2010 ; Vol. 21, No. 5. pp. 532-542.
@article{fd6c6c39e0234d188bbae5dffdd4c774,
title = "The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis",
abstract = "Despite widespread use of anti-CD20 antibodies as therapeutic agents for oncologic and autoimmune indications, precise descriptions of killing mechanisms remain incomplete. Complement-dependent cytolysis and antibody-dependent cell-mediated cytotoxicity are indicated as modes of target cell depletion; however, the importance of apoptosis induction is controversial. Studies showing that the therapeutic anti-CD20 antibody rituximab (Rituxan) mediates apoptosis of tumor cell targets in vitro after cross-linking by anti-Fc reagents suggest that enhancement strategies applied to Fc-independent activities for anti-CD20 antibodies could improve therapeutic efficacy. An anti-CD20 antibody designated DXL625, with autophilic properties such as increased binding avidity, is shown here to independently induce caspase-mediated apoptosis of an established B-cell lymphoma line in vitro. Depletion of membrane cholesterol or chelation of extracellular calcium abrogated the pro-apoptotic activity of DXL625, indicating that intact lipid rafts and calcium are required for this activity. The Fc-mediated complement-dependent and antibody-dependent cellular killing mechanisms are maintained by DXL625 despite conjugation of the parental Rituxan antibody to the autophilic DXL peptide sequence. This study shows a strategy for improving anti-CD20 immunotherapy by endowing therapeutic antibodies with self-interacting properties.",
keywords = "Apoptosis, CD20 receptor, DXL625, Rituxan",
author = "Bingaman, {Marc G.} and Basu, {Gargi D.} and Golding, {Tiana C.} and Chong, {Samuel K.} and Lassen, {Andrew J.} and Kindt, {Thomas J.} and Lipinski, {Christopher A.}",
year = "2010",
month = "6",
doi = "10.1097/CAD.0b013e328337d485",
language = "English (US)",
volume = "21",
pages = "532--542",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis

AU - Bingaman, Marc G.

AU - Basu, Gargi D.

AU - Golding, Tiana C.

AU - Chong, Samuel K.

AU - Lassen, Andrew J.

AU - Kindt, Thomas J.

AU - Lipinski, Christopher A.

PY - 2010/6

Y1 - 2010/6

N2 - Despite widespread use of anti-CD20 antibodies as therapeutic agents for oncologic and autoimmune indications, precise descriptions of killing mechanisms remain incomplete. Complement-dependent cytolysis and antibody-dependent cell-mediated cytotoxicity are indicated as modes of target cell depletion; however, the importance of apoptosis induction is controversial. Studies showing that the therapeutic anti-CD20 antibody rituximab (Rituxan) mediates apoptosis of tumor cell targets in vitro after cross-linking by anti-Fc reagents suggest that enhancement strategies applied to Fc-independent activities for anti-CD20 antibodies could improve therapeutic efficacy. An anti-CD20 antibody designated DXL625, with autophilic properties such as increased binding avidity, is shown here to independently induce caspase-mediated apoptosis of an established B-cell lymphoma line in vitro. Depletion of membrane cholesterol or chelation of extracellular calcium abrogated the pro-apoptotic activity of DXL625, indicating that intact lipid rafts and calcium are required for this activity. The Fc-mediated complement-dependent and antibody-dependent cellular killing mechanisms are maintained by DXL625 despite conjugation of the parental Rituxan antibody to the autophilic DXL peptide sequence. This study shows a strategy for improving anti-CD20 immunotherapy by endowing therapeutic antibodies with self-interacting properties.

AB - Despite widespread use of anti-CD20 antibodies as therapeutic agents for oncologic and autoimmune indications, precise descriptions of killing mechanisms remain incomplete. Complement-dependent cytolysis and antibody-dependent cell-mediated cytotoxicity are indicated as modes of target cell depletion; however, the importance of apoptosis induction is controversial. Studies showing that the therapeutic anti-CD20 antibody rituximab (Rituxan) mediates apoptosis of tumor cell targets in vitro after cross-linking by anti-Fc reagents suggest that enhancement strategies applied to Fc-independent activities for anti-CD20 antibodies could improve therapeutic efficacy. An anti-CD20 antibody designated DXL625, with autophilic properties such as increased binding avidity, is shown here to independently induce caspase-mediated apoptosis of an established B-cell lymphoma line in vitro. Depletion of membrane cholesterol or chelation of extracellular calcium abrogated the pro-apoptotic activity of DXL625, indicating that intact lipid rafts and calcium are required for this activity. The Fc-mediated complement-dependent and antibody-dependent cellular killing mechanisms are maintained by DXL625 despite conjugation of the parental Rituxan antibody to the autophilic DXL peptide sequence. This study shows a strategy for improving anti-CD20 immunotherapy by endowing therapeutic antibodies with self-interacting properties.

KW - Apoptosis

KW - CD20 receptor

KW - DXL625

KW - Rituxan

UR - http://www.scopus.com/inward/record.url?scp=77951294947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951294947&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328337d485

DO - 10.1097/CAD.0b013e328337d485

M3 - Article

VL - 21

SP - 532

EP - 542

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -